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ABSTRACT
Background Despite the success of immune checkpoint 
inhibitors against PD- L1 in the clinic, only a fraction of 
patients benefit from such therapy. A theoretical strategy 
to increase efficacy would be to arm such antibodies with 
Fc- mediated effector mechanisms. However, these effector 
mechanisms are inhibited or reduced due to toxicity 
issues since PD- L1 is not confined to the tumor and also 
expressed on healthy cells. To increase efficacy while 
minimizing toxicity, we designed an oncolytic adenovirus 
that secretes a cross- hybrid Fc- fusion peptide against 
PD- L1 able to elicit effector mechanisms of an IgG1 and 
also IgA1 consequently activating neutrophils, a population 
neglected by IgG1, in order to combine multiple effector 
mechanisms.
Methods The cross- hybrid Fc- fusion peptide comprises 
of an Fc with the constant domains of an IgA1 and IgG1 
which is connected to a PD-1 ectodomain via a GGGS 
linker and was cloned into an oncolytic adenovirus. We 
demonstrated that the oncolytic adenovirus was able to 
secrete the cross- hybrid Fc- fusion peptide able to bind 
to PD- L1 and activate multiple immune components 
enhancing tumor cytotoxicity in various cancer cell lines, 
in vivo and ex vivo renal- cell carcinoma patient- derived 
organoids.
Results Using various techniques to measure cytotoxicity, 
the cross- hybrid Fc- fusion peptide expressed by the 
oncolytic adenovirus was shown to activate Fc- effector 
mechanisms of an IgA1 (neutrophil activation) as well as 
of an IgG1 (natural killer and complement activation). The 
activation of multiple effector mechanism simultaneously 
led to significantly increased tumor killing compared with 
FDA- approved PD- L1 checkpoint inhibitor (Atezolizumab), 
IgG1- PDL1 and IgA- PDL1 in various in vitro cell lines, in 
vivo models and ex vivo renal cell carcinoma organoids. 
Moreover, in vivo data demonstrated that Ad- Cab did not 
require CD8 + T cells, unlike conventional checkpoint 
inhibitors, since it was able to activate other effector 
populations.
Conclusion Arming PD- L1 checkpoint inhibitors with 
Fc- effector mechanisms of both an IgA1 and an IgG1 can 
increase efficacy while maintaining safety by limiting 
expression to the tumor using oncolytic adenovirus. 
The increase in tumor killing is mostly attributed to 
the activation of multiple effector populations rather 
than activating a single effector population leading to 
significantly higher tumor killing.
INTRODUCTION
Immune checkpoint inhibitor (ICI) thera-
pies have been established as a potent treat-
ment option for a plethora of tumor types 
and have significantly expanded the thera-
peutic armamentarium in oncology. Such 
agents target immune inhibitory receptors 
and interrupt coinhibitory signaling path-
ways, abrogating their immunosuppressive 
function and consequently revitalizing anti-
tumor immune response. The consequent 
restoration of immune- mediated elimination 
of tumor cells leads to long- term, sustained 
tumor responses,1 2 resulting in their approval 
as first- line treatments for a growing list of 
malignancies.3 Nevertheless, accumulating 
evidence indicate that checkpoint inhibitors 
can only benefit a fraction of patients.4
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In spite of such limitations, there has been a shift of 
focus in improving ICIs therapeutic efficacy. All clinically 
approved ICIs are antibodies that primarily act as antago-
nizing agents with their main mechanism of action being 
the reconstitution of a T- cell response by disrupting an 
immunosuppressive axis.5 Nevertheless, ICIs are either 
limited or entirely not able to elicit crucial antibody- 
dependent effector mechanisms6 such as complement- 
dependent cytotoxicity (CDC) or antibody- dependent 
cell cytotoxicity/phagocytosis (ADCC/ADCP) which are 
pertinent to an antibody. Based on clinical data, activa-
tion of effector mechanisms are a necessity for thera-
peutic antibodies to achieve tumor clearance.7 Moreover, 
effector mechanisms such as ADCC and CDC have been 
noticed to be an essential requirement for enhanced anti-
tumor responses for some modified ICIs against CTLA-
48 or PD- L1.9 10 Thus, equipping or enhancing ICIs with 
such effector mechanism via the Fc- fragment may lead to 
improved efficacy, resulting in higher response rates in 
the clinic.
In the clinic, all therapeutic antibodies against cancer 
are of the IgG isotype and predominantly of the IgG1 
subtype. This is primarily due to the ability of an IgG to 
activate the complement system and natural killer cells 
(NK), leading to tumor killing. Yet, IgG fails to efficiently 
activate the most abundant leukocyte population able to 
infiltrate solid tumors, neutrophils. This is mostly due 
to the relatively high expression of inhibitory Fc-γIIB 
(CD32B)11 and Fc-γIIIB (CD16B),12 which do not contain 
any signaling motif yet has been seen to block the activa-
tion of ADCC.13 In order to capitalize on such a prom-
ising population, IgA antibodies have been used since 
they bind to the Fc-α receptor, CD89, which is highly 
expressed on neutrophils, monocytes and macrophages 
consequently eliciting ADCC or ADCP.14 15 In addition, 
the Fc-α-mediated activation of neutrophils by IgA anti-
bodies has been shown to be more effective in tumor 
killing than the Fc-γ-mediated effector mechanisms by 
IgG antibodies in multiple types of cancers.16 However, 
it has been shown that the addition of both IgG and IgA 
antibodies further enhances tumor cytotoxicity.17
Here, we have developed a Fc- fusion peptide against 
PD- L1 consisting of a cross- hybrid Fc region containing 
constant regions of an IgG1 and an IgA1, termed IgGA,18 
connected to a PD-1 ectodomain, carrying mutations that 
increase its affinity towards PD- L1 via a glycine linker. 
However, carrying a competent/functional Fc region 
can be a double- edged sword since immune checkpoints 
are expressed ubiquitously and such antibodies are 
systemically administered, frequently causing irAEs.19 To 
circumvent this obstacle, we limited the expression of the 
Fc- fusion peptide directly into the tumor microenviron-
ment by cloning it into an oncolytic adenovirus. Oncolytic 
viruses have become ideal gene therapy vehicles because 
they are able to selectively infect and kill tumor cells while 
leaving healthy tissues intact, as shown in preclinical trials 
and patients.20 Moreover, preclinical and clinical research 
has demonstrated that these agents specifically express 
their transgenes to the tumor microenvironment with 
limited leakage.21 22
We demonstrated that the cross- isotype Fc region gives 
the ICI the ability to elicit effector mechanisms of both 
an IgA and an IgG isotype in various tumor cell lines. 
The subsequent activation of multiple effector mecha-
nisms further enhanced tumor killing and was shown 
to be superior than a PD- L1 IgG1 antibody or Atezoli-
zumab, a currently approved FDA ICI. To further eval-
uate the efficacy of the Fc fusion peptide, we tested our 
engineered adenovirus (named Ad- Cab) in multiple in 
vivo tumor models and showed significantly enhanced 
tumor growth control as compared with unarmed adeno-
virus or ICI against murine PD- L1. Finally, to examine 
the oncolytic efficacy of the Ad- Cab in a testing platform 
with high clinical response predictability, we used renal 
cell carcinoma patient- derived organoids (RCC PDO). In 
this model, we showed significantly enhanced tumor cell 
lysis as compared with Atezolizumab or an anti- PD- L1 IgG 
antibody with functional Fc region.
Cell lines and antibodies
Human lung cancer cell line A549 ((ATCC Cat# 
CRM- CCL-185, RRID:CVCL_0023), human breast 
cancer cell line MDA- MB-436 ((ATCC Cat# HTB-130, 
RRID:CVCL_0623), murine colon adenocarcinoma CT26 
(ATCC Cat# CRL-2638, RRID:CVCL_7256), murine 
breast cancer cell line 4T1 (ATCC Cat# CRL-2539, 
RRID:CVCL_0125) and murine skin cancer cell lines 
B16F1 (ATCC Cat# CRL-6323, RRID:CVCL_0158) and 
B1610 (ATCC Cat# CRL-6475, RRID:CVCL_0159) were 
purchased from the American Type Culture Collection 
(ATCC) after 2013. Cell lines were thawed at passage 5 
and kept in culture until reaching passage 15. All cell 
lines were authenticated by the ATCC, cultured under 
appropriate conditions and regularly checked for myco-
plasma contaminations. Atezolizumab and IgG1- PD- L1 
were purchased from Invivogen. IgA- PD- L1 was kindly 
provided by Dr Jeanette Leusen of Utrecht University 
Medical University.
Preparation of conditionally replicating adenovirus and 
transgene modifications
All adenoviruses were generated as conditionally repli-
cating adenoviruses using standard protocols previously 
described.23 Ad- Cab and unarmed viruses are of the 
chimeric 5/3 serotype with a 21- nucleotide deletion 
in the E1A region resulting in selective replication in 
Rb- deficient pathway cells. Ad- RFP has the same genetic 
modification in E1A but originates from the serotype 5. 
All transgenes were cloned by replacing the gp19K+7.1K 
region in the E3 gene using Gibson- Assembly previously 
described.24
Generation of Fc-fusion peptide
The Fc- Fusion peptide consists of a chimeric Fc containing 
constant domains of an IgG1 and IgA connected to an 
enhanced PD-1 ectodomain via five GGGS linkers. The 
copyright.
 on A















3Hamdan F, et al. J Immunother Cancer 2021;9:e003000. doi:10.1136/jitc-2021-003000
Open access
cross- hybrid Fc has been described18 as well as the PD-1 
ectodomain.25
Cell viability assays
A total of 10,000 cells were plated in a 96- well plate 
overnight and subsequently infected at different MOIs. 
Three- day postinfections cell viability was determined 
by MTS according to the manufacturer’s protocol (Cell 
Titer 96 AQueous One Solution Cell Proliferation Assay; 
Promega, Nacka, Sweden). Spectrophotometric data 
were acquired with Varioskan LUXMultimode Reader 
(Thermo Scientific, Carlsbad, C, USA) operated by 
SkanItsoftware.
Competition assay
A total of 100,000 A549 cells were plated in a 96- well, 
washed with PBS and incubated with various concen-
trations of purified Fc- fusion peptide for 45 min on 
ice. Next, 10 ug/mL of Atezolizumab (Invivogen, Cat# 
hpdl1- mab12) was added and incubated for 30 min on 
ice. Atezolizumab was then detected by staining with 
a PE labeled antihuman IgG (BioLegend Cat# 409303, 
RRID:AB_10900424). Cells where then washed and resus-
pended in PBS. Competition was then quantified by flow 
cytometry using the BD Accuri 6 plus (BD Biosciences) 
and analyzed using the FlowJo software (FlowJo, V.10.7.1, 
RRID:SCR_008520).
PBMCs, PMN and serum collection
A total of 40 mL of blood was collected from healthy 
volunteers in BD Vacutainer collection tubes (BD Biosci-
ence) and allowed to clot for 30 min at room tempera-
ture. After clotting, clots were removed, and samples 
centrifuged for 5 min at 2500 rpm. Separated serum was 
collected and samples from 15 volunteers were pooled 
together. Polymorphonuclear cells (PMNs) and periph-
eral blood mononuclear cells (PBMCs) were isolated 
from buffy coats as previously described.18 The PBMC and 
PMN layers were subsequently removed between serum 
and Ficoll or in the Histopaque layer, respectively, and 
cultured in 1xRPMI (Roswell Park Memorial Institute, 
Gibco, Cat# 21875034)-
Mixed leukocyte reaction
Monocytes were first isolated from PBMCs as previously 
described. Following isolation, monocytes were differen-
tiated using DMEM low glucose supplemented with 10% 
FBS, 500 U/mL of IL-4 (PeproTech, #200–04) and 250 U/
mL of GM- CSF (Adcam, ab88382) for 7 days. PBMCs from 
a different donor were freshly isolated, labeled with CFSE 
and incubated with monocyte- derived dendritic cells for 
5 days at a ratio of 1:10 in the presence of 1 µg/mL of 
Atezolizumab or isolated IgGA Fc- fusion peptide. Cells 
from the supernatant were then collected and using flow-
cytometry CFSE was measured in CD3 + CD8+ T cells.
Complement-dependent cytotoxicity assay
A total of 100,000 cancer cells were plated per well to a 
96- well plate and infected with 10 or 100 MOI of virus 
for 48 hours at 37°C. Then, complement active pooled 
human serum or heat inactivated serum (by incubating 
serum at 56°C for 30 min) was added to a final concen-
tration of 15.5% and incubated for 4 hours. Subsequently, 
lysis was quantified by washing cells and stained with 
7- amino- actinomycin D (7- AAD) (eBioscience, Cat# 
00-6993-50) and measured by flow cytometry.
Antibody-dependent cell cytotoxicity assays
ADCC assays were performed through measuring cell 
killing by determining the amount of LDH released using 
a colometric assay (CyQUANT LDH Cytotoxicity Assay, 
Cat# C20303). A total of 15,000 cells were then seeded 
and infected with 10 or 100 MOI of virus for 48 hours 
at 37°C. Afterwards, PBMCs or PMNs were added in a 
100:1 or 40:1 ratio (E: T), respectively, and incubated for 
4 hours at 37°C. LDH was measured using the mentioned 
kit and percent cytotoxicity was calculated as follows: 
Percent cytotoxicity = (“experimental” – “effector plus 
target spontaneous”)/(“target maximum” – “target spon-
taneous”) × 100%, where “experimental” corresponds to 
the signal measured in a treated sample, “effector plus 
target spontaneous” corresponds to the signal measured 
in the presence of PMN or PBMC and tumor cells 
alone and “target maximum” corresponds to the signal 
measured in the presence of detergent lysed tumor cells
Antibody-dependent cell phagocytosis
Around 2,000,000 freshly isolated PBMCs were cultured 
in a T25 culture flask for 2 hours at 37°C. Floating cells 
were removed, and adherent monocytes were differen-
tiated into macrophages by culturing in RPMI supple-
mented with 50 µg/mL of M- CSF (Sigma Aldrich, Cat# 
M6518) for 7 days at 37°C. 10,000 cells were incubated 
and infected with indicated viruses at 10 and 100 MOI 
for 48 hours. Cells were then labeled with CFSE (Ther-
moFisher), according to the manufactures instructions 
and monocyte- differentiated macrophages were added 
at a 5:1 effector:target ratio. After 4 hours, supernatant 
containing macrophages were removed and CFSE was 
measured using flow cytometry.
Trogocytosis
Trogocytosis was performed as previously described.26 
In brief, 5000 cells were infected with 100 MOI of 
virus and incubated for 48 hours at 37°C. Cell’s lipid 
membrane were labeled with 5 um of DiO (ChemCruz, 
Cat# sc-214168), a lipophilic membrane dye, for 30 min 
at 37°C. Cells were washed and incubated with PMNs at 
a 40:1 (E:T) ratio. Samples were fixed using Paraformal-
dehyde (Sigma Aldrich) and measured using flow cytom-
etry. Trogocytosis was measured by first gating on the 
neutrophil population and measuring the mean fluores-
cent intensity (MFI) of cells positive for DiO.
Real-rime quantitative analaysis (xCELLigence assay)
The ability to induce ADCC was analyzed using the 
impedance- based real- time cytotoxicity assay with the 
xCELLigence system (ACEA Biosciences, San Diego, 
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California, USA). In each well, 25,000–100,000 cells were 
plated for 24 hours. Five µg/mL of designated antibody or 
purified Fc- fusion peptide was added along with PBMCs 
and PMNs at a 10:1 and 4:1 effector:target ratio. Cell 
index was measured every 5 min for a period of 6 hours. 
Killing rate was obtained by constructing a linear trend-
line and calculating the slope.
Live cell imaging
Imaging target to effector cell contacts, 15,000 A549 cells 
were plated per well of a 24 well plate (Corning) over-
night. Cells were imaged for 30 min and subsequently 
treated with 10 µg/mL of indicated Fc- fusion peptides 
and PBMCs were added at 10:1 E:T ratio. The videos were 
acquired using an ANDOR Spinning Disc Microscope 
equipped with a Zyla camera (SR Apochromat ×100 objec-
tive, NA 1.49). Images were acquired every 5 min over the 
course of 2 hours 20 min.
Live- cell killing assay was performed by plating 
100,000 A549 cells per well of a 24 well plate (Corning) 
overnight. Fifteen minutes prior to imaging, cells were 
incubated with 3 µM of Incucyte Caspace3/7 green 
apoptosis assay reagent (Sartorius, Cat# C10423). Cells 
were imaged using the IncuCyte S3 live cell analysis 
system equipped with a 10× air objective for a total 
of 24 hours. Images were acquired every 15 min and 
four fields of view were imaged per well. After 1 hour 
of imaging, cells were treated with indicated anti-
bodies at 5 µg/mL and PMNs and PBMCs were added 
at 100:1 and 40:1 E:T ratios, respectively. Treated cells 
were returned to the IncuCyte S3 and imaged for the 
remainder 23 hours. Videos were processed with the 
IncuCyte analysis software (IncuCyte Chemotaxis Soft-
ware, RRID:SCR_017316) and are displayed as four 
fields of view per second.
Whole blood assay
Blood was collected from three healthy volunteers in 
BD Vacutainer Heparin plasma tubes. A total of 200 µL 
of unprocessed blood was then incubated with 20 µg/
mL of Traztuzumab or IgGA Fc- fusion peptide for 24 
hours. After incubation, samples were treated with ACK 
lysing buffer (Gibco) to remove red blood cells. Cells 
were then stained with CD3, CD15, CD14, CD56 and 
CD11c to determine immune cell populations. Absolute 
numbers were calculated by using precision count beads 
(Biolegend, Cat# 424902) and following the manufac-
turers instructions.
Renal cell carcinoma patient-derived samples and ethical 
considerations
Renal cell carcinoma samples were obtained from four 
patients that underwent surgical removal of the tumors. 
Tumor samples were collected and delivered directly 
from the Peijas Hospital. The study was conducted in 
accordance with the declaration of Helsinki and patients 
gave their written consent.
Syngeneic animal experiments
All animal experiments were reviewed and approved by 
the Experimental Animal Committee of the University 
of Helsinki and the Provincial Government of Southern 
Finland (license number ESAVI/11895/2019). Around 
4–6- week- old immunocompetent female BALB/c mice, 
purchased from Envigo (Venray, Netherlands), injected 
in the right flank with either 500,000 CT26 cells or 
300,000 4T1 cells and were treated 7, 9, 11, 13, 19 and 
21- days post- tumor implantation with 1×109 viral particles 
of virus intratumorally or 100 µg/mL of mPD- L1 (Bio X 
Cell Cat# BE0101, RRID:AB_10949073) intraperitoneally. 
Viral treatments were administered in 25 µL volume while 
antibodies were given in 100 µL. Tumor size was measured 
every second day and calculated using the following 
formula: (long side)×(short side)2/2. Mice were sacri-
ficed when any side of the tumor reached 16 mm.
As for in vivo CD8 depletion, mice were initially injected 
intraperitoneally with 500 µg of depleting CD8 antibody 
(Bio X Cell Cat# BE0061, RRID:AB_1125541) 1 day prior 
to treatment and then 100 µg every 2 days for the duration 
of the experiment.
At day 23 (CT26) and 15 (4T1) post- tumor implanta-
tion, two animals from each group were sacrificed and 
blood and tumors were collected. Blood was allowed to 
clot, then centrifuged at 500 g for 15 min and serum was 
subsequently collected. Tumors were crushed through a 
0.22 µm cell strainer, centrifuged at 500 g for 10 min and 
supernatant collected. His- tagged proteins from serum 
and tumor supernatant was tested using a His- tag ELISA 
kit (Cell Biolabs, Cat#AKR-130).
Immune deficient NS (NOD/SCID) mice
Four–six- week- old Nod.CB17- Prkdcscid/NCrCrl mice were 
purchased from Charles River and were injected with 
 5x106 A549 cells in the right flank. Subsequently, 5×106 
freshly isolated PBMCs were then injected intraperitone-
ally. After tumors were palpable, mice were treated two 
times (with a 3- day break in between) with 1×108 viral 
particles intratumorally.
Flow cytometry analysis
Flow cytometry analysis was done with either BD Accuri 6 
plus (BD Bioscience) or Fortessa (BD Bioscience). Anti-
bodies used include APC antimouse Ly6C (BioLegend 
Cat# 128015, RRID:AB_1732087), FITC antimouse 
NK1.1 (Thermo Fisher Scientific Cat# 11-5941-85, 
RRID:AB_465319), PE antimouse PD-1 (BioLegend 
Cat# 135206, RRID:AB_1877231), PE anti- Ly6G (BD 
Biosciences Cat# 551461, RRID:AB_394208), PerCP 
Cy5.5 antimouse CD11b (Thermo Fisher Scientific Cat# 
45-0112-82, RRID:AB_953558), BV650 antimouse F4/80 
(BD Biosciences Cat# 743282, RRID:AB_2741400), 
PeCy7 antimouse CD4 (Thermo Fisher Scientific Cat# 
25-0041-82, RRID:AB_469576), PerCp/Cy5.5 antimouse 
CD107a (BioLegend Cat# 121626, RRID:AB_2572055), 
Pacific Blue antimouse CD3 (BioLegend Cat# 100214, 
RRID:AB_493645), PECy7 antimouse CD11c (Thermo 
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Fisher Scientific Cat# 25-0114-82, RRID:AB_469590), 
FITC antihuman CD56 (BioLegend Cat# 304604, 
RRID:AB_314446), PerCP antihuman CD8alpha 
(BioLegend Cat# 300922, RRID:AB_1575072), PE- Cy5 
antihuman CD4 (Thermo Fisher Scientific Cat# 
15-0049-42, RRID:AB_1582251), PE- Cy7 antihuman 
CD3 (BioLegend Cat# 300316, RRID:AB_314052), 
Pacific blue antihuman PD-1 (BioLegend Cat# 329915, 
RRID:AB_1877194), APC antihuman CD107a (BioLegend 
Cat# 328620, RRID:AB_1279055), APC antihuman 
CD11c (BioLegend Cat# 371505, RRID:AB_2616901), 
Pacific Blue antihuman CD15 (BioLegend Cat# 323021, 
RRID:AB_2105361) and PE antihuman CD14 (BioLegend 
Cat# 301805, RRID:AB_314187).
Renal cell carcinoma patient-derived organoid culturing
Frozen disassociated cells were grown in DMEM/F12 
media in 30% Matrigel (Corning, Cat# 354230) on 
ultralow attachment plates (ULA Corning, Cat# 3473). 
Cells were split and washed with gentle cell disassoci-
ation media (Stemcell, Cat# 07174) and 10,000 cells 
mixed with 30% Matrigel and grown for 1 week before 
the experiment. DMEM/F12 media was supplemented 
with 5% FBS, 8,4 ng/mL of cholera toxin (Sigma, Cat# 
C8052), 0.4 µg/mL hydrocortisone (Sigma, Cat# H4001), 
10 ng/mL epidermal growth factor (Corning, Cat# 
354052), 24 µg/mL Adenine (Sigma, Cat# A8626), 5 µg/
mL insulin (Sigma, 91077C) and 10 µM of Y-27632 RHO 
inhibitor (Sigma, Cat# SCM075).
Immunofluorescence and flow-cytometry on renal cell 
carcinoma patient-derived organoids
Gentle cell disassociation media was used on organoid 
cultures, and cells washed and carefully pipetted to disas-
sociate cells. Cells were plated on 8 well Nunc; Lab- Tek; 
II Chamber Slides and cultured for 4 days. Cells were 
fixed in 4% cold paraformaldehyde and stained with 
CAIX (Novus Cat# NBP1-51691, RRID:AB_11011250), 
Vimentin (2D1) (Novus, Cat# 92 687AF647), or Cytoker-
atin pan (AE-1/AE-3)(Novus Cat# NBP2- 33200AF750, 
RRID:AB_2868569) or Alexa Fluor 633 Phalloidin (Invi-
trogen, Cat# A22284) Microscopy pictures were taking 
using an EVOS FL cell imaging system (Thermo Fisher 
Scientific).
Ad-RFP infection and PBMC co-culture with renal cell 
carcinoma patient-derived organoids
A total of 100,000 VPs of Ad5- RFP were added on top of 
the media of already cultured organoids and RFP expres-
sion was then monitored. Cell viability of PDOs was moni-
tored by adding 1 µM of Calcein AM (Thermo Fisher 
Scientific, Cat# C1430).
As for coculturing, a total of 15,000 isolated PBMCs 
were first stained with 1 µM Calcein AM and added on 
top of the media of RCC PDOs and cultured for 4 hours at 
37°C. PBMC invasion was then visualized using the EVOS 
FL cell imaging system
Antibody-dependent cell cytotoxicity assays with renal cell 
carcinoma patient-derived organoid
RCC PDOs were infected with viruses at 10 or 100 MOI 
by adding it on top of the supernatant media and incu-
bated for 72 hours at 37°C. PBMCs and PMNs were then 
added individually or combined at 100:1 and 40:1 (E:T), 
respectively. The number of cells in the organoids were 
assumed to be 10,000. After 4 hours of incubation at 37℃, 
cell killing was measured by determining the amount of 
LDH released using a colometric assay (CyQUANT LDH 
Cytotoxicity Assay, Cat# C20303). Specific lysis was then 
calculated as stated before.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
7 (GraphPad Software, La Jolla, California, USA). Data 
were analyzed using an unpaired t- test where n≥3. Levels 
of significance were set at *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. Error bars represent SEM.
RESULTS
Characterization of an oncolytic adenovirus expressing IgGA-
chimeric anti-PD1 Fc-fusion peptides
In this study, we generated an oncolytic adenovirus, 
Ad- Cab (Adenovirus- ChimericAntibody), expressing a 
chimeric IgG- IgA (IgGA) Fc linked to an enhanced PD-1 
ectodomain via a glycine linker able to bind to PD- L1 
(figure 1A). This was cloned in the gp19K+7.1K region of 
the E3A gene (figure 1B) and with an MTS cell viability 
assay, we could show that the genetic modification did 
not affect the oncolytic fitness or replication of the virus 
(online supplemental figure S1A).
First, the Fc- fusion peptide production was tested by 
western blot analysis. Ad- Cab was able to secrete a 100 kDa 
Fc- fusion peptide, under native conditions, in the super-
natant of A549 cells at 48 hours after incubation (online 
supplemental figure S1B). As expected, the Fc- fusion 
peptide comprised of a homodimer connected via a 
sulfide bridge, since a 50 kDa band was observed under 
denaturing conditions (online supplemental figure S1B). 
Next, we assessed the amount of Fc- fusion peptide secreted 
at different time points of infection. After 1 day of infec-
tion in A549 cells, Ad- Cab secreted approximately 2 µg of 
the Fc- fusion peptide and production kept increasing till 
day 3 reaching 7 µg (figure 1C). To assess whether the 
produced Fc- fusion peptide could bind to PD- L1, we 
performed a competition assay with a commercially avail-
able anti- PD- L1 (Atezolizumab), a well- established binder 
of PD- L1 and disruptor of the PD-1/L1 axis. To this end, 
we coincubated A549 cells with increasing concentrations 
of Fc- fusion peptides, purified from the supernatant of 
infected cells, followed by the addition of 10 µg/mL of 
Atezolizumab. Detection of bound Atezolizumab to PD- L1 
was then analyzed by adding a secondary PE labeled anti-
human IgG not able to recognize the Fc- fusion peptide. 
When no Fc- fusion peptide was added Atezolizumab was 
able to bind to PD- L1 (figure 1D). Yet, as the concentration 
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Figure 1 Characterization of Ad- Cab. (A) Graphical representation of the IgGA Fc- fusion protein; the cross- isotype Fc is made 
up of the CH chains 2 and 3 of an IgA2 (purple) and IgG1 (orange) attached to an PD-1 ectodomain (green) via a glycine linker. 
The IgGA Fc employs effector mechanism of both an IgG1 and IgA2. (B) Schematic representation of oncolytic adenovirus 5/3 
delta 24 (Ad5/3 Δ24) constructs with modifications in the E1, E3 and fiber regions. Black inverted triangles represent deletions. 
Both unarmed Ad5/3 Δ24 (Unarmed) and IgGA PD- L1 Ad-5/3 △24 (Ad- Cab) have a 24 base- pair deletion in the E1 region, 
leading to conditionally replicate in Rb- deficient cells, and a serotype 5 fiber knob with serotype 3 knob. The IgGA PD- L1 fusion 
protein cassette consisted of CMV promoter and enhancer and was cloned into the gp19k+71 .k region. (C) Quantification of 
IgGA Fc- fusion proteins over time. A549 cells were infected with 100 MOI of Ad- Cab and Unarmed virus and supernatants 
were collected at different indicated time points. IgGA Fc- fusion proteins were purified, and concentration was assessed by 
measuring absorbance at 280 nm. (D) Competitive assay between Atezolizumab and Ad- Cab. A549 cells were incubated with 
different concentrations of purified IgGA Fc- fusion proteins from Ad- Cab and followed by addition of 10 µg/mL Atezolizumab. 
Atezolizumab binding was then analyzed using an PE- labeled antihuman IgG not recognizing IgGA Fc- fusion proteins. (E) 
Coincubation of monocyte- derived dendritic cells with allogenic CFSE stained T cells, at a 1:10 ratio, in the presence of 1 µg/mL 
of Atezolizumab or isolated IgGA Fc- fusion peptide. CFSE was then measure from CD3 + CD+ 8 T cells and the expansion index 
was calculated. CH, constant heavy; CMV, cytomegalovirus.
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of the Fc- fusion peptide increased, Atezolizumab binding 
decreased substantially (figure 1D). Moreover, to further 
demonstrate PD- L1 binding, we conducted live cell 
imaging to observe whether the Fc- fusion peptide could 
mediate close cell- contacts when PBMC were coincu-
bated with lung carcinoma A549 cells. When Ad- Cab 
(online supplemental movie S1) was added, PBMCs 
were shown to be in clear proximity to A549 compared 
with when we added Atezolizumab, a clinical PD- L1 anti-
body holding a N298A mutation abrogating Fc- binding 
(online supplemental movie S2). To test the ability for the 
Fc- fusion peptide to activate CD8 + T cells, an allogenic 
mixed leukocyte reaction was performed. In this assay, 
monocytic- differentiated dendritic cells from one donor 
were mixed with isolated CFSE stained PBMCs from 
another donor to mimic the immunosuppressive effects 
of PD- L1/PD1 interactions. Samples were treated with or 
without Atezolizumab or purified IgGA Fc- fusion peptide 
to test whether the blocking of PD- L1 could induce a T 
cells expansion (figure 1E). When Atezolizumab and 
IgGA Fc- fusion peptide were added, a clear expansion of 
CD8 + T cells was observed, correlating with a decrease in 
CFSE compared with untreated. When calculating their 
expansion index, both Atezolizumab and IgGA Fc- fu-
sion peptide were higher than the mock. Taken together, 
we demonstrated that Ad- Cab can secrete high levels of 
Fc- fusion peptide that is able to bind to PD- L1, outcom-
pete Atezolizumab and activate CD8 + T cells.
The secreted Fc-fusion peptides activate effector mechanisms 
of an IgG1 and an IgA1
After testing expression and binding, we examined the 
ability of the Fc- fusion peptides to activate antibody effector 
mechanisms. Since the Fc entails a hybrid of an IgG1 and 
an IgA1, CDC and ADCC were tested with both PMN 
and PBMCs on six different human and murine tumor 
cell lines expressing varying levels of PD- L1 (figure 2A). 
Murine breast cancer (4T1), murine colon carcinoma 
(CT26) and murine melanoma cell lines (B16F10 and 
B16F1) were used since oncolytic human adenoviruses 
cannot induce oncolysis and cytotoxicity in most murine 
cell lines and thus the effects seen can then be attributed 
to the Fc- activation of effector mechanisms. Cells were 
first infected with either Ad- Cab or unarmed oncolytic 
adenovirus (Ad-5/3 Δ24) at two different MOIs (10 and 
100) for 2 days to limit oncolysis with human cell lines 
(MDA- MB-436 and A549). Subsequently, when comple-
ment active serum was added, cell lysis could be observed 
with Ad- Cab infected cells (figure 2B). Already at MOI 10, 
cell lysis was occurring and was further augmented as the 
MOI increased to 100 in all six cell lines. As expected, cell 
lysis was not shown with the control virus (Ad5/3- delta 
24) in all conditions, further attributing cell death to 
CDC induction, especially in the human cell lines where 
viral oncolysis can be induced.
ADCC assays were then tested with two different 
immune populations: PBMCs (figure 2C) and PMNs 
(figure 2D). In contrast to CDC, at MOI 10 minimal or 
no induction of ADCC could be seen with all cell lines 
infected with Ad- Cab when PBMCs or PMNs were added. 
Nevertheless, when the MOI increased to 100, cell lysis 
was observed with both populations. Interestingly, both 
PMNs and PBMCs were able to elicit similar levels of cyto-
toxicity with all the cells.
Finally, we wanted to test the ability of Ad- Cab to acti-
vate macrophages and induce ADCP. The ability to elicit 
ADCP was determined by the uptake of CFSE by macro-
phages from the tumor cell lines labeled with CFSE. 
At MOI 10, no uptake of CFSE was observed with any 
condition yet at MOI 100, an increase of CFSE uptake 
by the macrophages could be observed in all cell lines 
when Ad- Cab was added (figure 2E). Overall, the data 
demonstrate that the secreted Fc- fusion peptide can 
induce the effector mechanisms of both an IgG1 and 
an IgA.
Trogocytosis drives the PMN-mediated ADCC
It has been previously shown that in order to initiate 
ADCC in vitro, PMNs adhere to the target cells estab-
lishing an immunological synapse with the antibody- 
opsonized tumor cells.27 This subsequently causes the 
disruption of their plasma membrane and the endocy-
tosis of cytoplasmic fragments, leading to a necrotic type 
of cell death termed trogocytosis. In order to explore 
the possible nature of the cytotoxic mechanism during 
PMN- mediated ADCC, we quantified the transfer of 
membrane from tumor cells to PMNs by flow cytometry. 
Virally infected cells had their lipid membrane labeled 
with 3,30- dioctadecyloxacarbocyanine perchlorate 
(DiO), after which unstained neutrophils were added to 
the cell culture. Neutrophils were first gated using the 
side and forward scatter since they are smaller than a 
tumor cell and also confirmed with neutrophil markers 
such as CD15 + and CD14− (online supplemental figure 
S2). Τhe MFI of DiO was then measured on these 
neutrophils after incubation in three different condi-
tions: without exposure to the target cells (figure 3A), 
with exposure to uninfected stained cells (figure 3B) 
and with exposure to Ad- Cab infected stained cells 
(figure 3C). When neutrophils were examined on their 
own, without former exposure to the target cells or 
when they were added to uninfected stained tumor cells, 
there was no DiO measured, and no membrane transfer 
had happened. Yet, when the neutrophils were added to 
Ad- Cab infected cells, an uptake of DiO was observed by 
PMNs. This implies the uptake of the lipid membrane 
of the infected tumor cells by the neutrophils, which 
is a characteristic of trogocytosis. The same procedure 
was performed using all six cell lines and an increase 
in DiO MFI in the neutrophils was noted only when 
neutrophils had previously been exposed to cancer cells 
infected with the Ad- Cab and not with the other controls 
used (figure 3D). Hence, these findings add evidence 
in support that one of the mechanisms in which PMNs 
employ ADCC with Ad- Cab is trogocytosis.
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Ad-Cab induces higher tumor cytotoxicity with multiple 
immune populations while leaving myeloid cells untouched
We hypothesized that a synchronous activation of the 
multiple branches of the immune system would lead to 
enhanced tumor cell killing and complete clearance of the 
tumor. To test this, we again performed the ADCC assays 
with different combinations of immune components such 
as PBMCs+PMNs or PBMCs+PMNS+serum with the same 
cell lines as previously expressing PD- L1 (figure 4A). Also, 
to further examine this, we used Atezolizumab, which 
Figure 2 Activation of multiple branches of the immune system. (A) The percentage of PD- L1 expression on all cell lines 
used in the assays. (B) FACS- based CDC assay against all six different cell lines with Ad- Cab and Unarmed virus. Cells were 
infected at two indicated MOIs, incubated for 48 hours and pooled serum from healthy volunteers was then added at a final 
concentration of 15.5%. After 4 hours at 37°C, cell lysis was measured using 7- AAD. ADCC against five different cell lines using 
either (C) PBMCs or (D) PMN as effector cells. Indicated viruses were added at 10 and 100 MOI and incubated for 48 hours. 
Subsequently, PBMCs and PMNs were added at an E:T ratio of 100:1 and 40:1, respectively, and lysis was by quantifying LDH 
release after 4 hours at 37°C. (E) ADCP was measured by incubating target cells with 10 or 100 MOI of Ad- Cab or unarmed virus 
for 48 hours. Then, cells were labeled with CFSE and macrophages were added at a 5:1 (effector:target) ratio. Phagocytosis was 
quantified by measuring the uptake of CFSE by macrophages. Levels of significance were set at *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. Error bars represent SD. AAD; amino- actinomycin D; ADCC, antibody- dependent cell cytotoxicity; ADCP, 



















9Hamdan F, et al. J Immunother Cancer 2021;9:e003000. doi:10.1136/jitc-2021-003000
Open access
holds a N298A mutation abrogating its effector mecha-
nisms, Atezolizumab without the mutation, designated 
IgG1- PD- L1, able to elicit effector mechanisms of an IgG1 
and an IgA- PD- L1. When each immune component was 
added individually (online supplemental figure S3B–D), 
Atezolizumab carrying the N298A mutation was not able 
to induce cell lysis. Interestingly, the functional IgG1 
PD- L1 antibody was able to induce similar cell lysis levels 
as the Fc- fusion peptides when the complement system 
or PBMCs were added. Nevertheless, the IgG1 PD- L1 
was able to induce only minimal cell lysis with PMNs 
compared with the Fc- fusion peptides. As expected, IgA- 
PD- L1 was only able to activate PMNs and not PBMCs or 
the complement system.
When PBMCs and PMNs were added together, a signif-
icant cytotoxicity augmentation, compared with the cell 
populations alone, was observed with Ad- Cab (figure 4B). 
This was not seen with IgG1- or IgA- PD- L1 where cell 
lysis levels remained like when PBMCs or PMNs were 
added alone, respectively. Meanwhile, when all three 
components (fresh human serum, PBMCs and PMNs) 
were added together, enhanced cytotoxicity could again 
be noticed with Ad- Cab and IgG1- PD L1 (figure 4C). 
Interestingly, IgG1 PD- L1 showed a significant increase 
in cell lysis compared with when serum or PBMCs 
were added together. This again further reinforced the 
added benefit of activating multiple immune branches. 
Moreover, the addition of serum to the combination of 
PBMCs+PMNs also significantly increased cell lysis with 
Ad- Cab. This increase in cell lysis almost reached full 
clearance of PD- L1 expressing cells. Notably, this syner-
gistic effect was demonstrated with B16F10, B16F1 and 
A549 cells but not with 4T1 and MDA- MB-436 cells. 






























































































































































































































































































































Figure 3 PMN’s mode of action during ADCC. Gating strategy (left) and histogram (right) of neutrophils incubated alone (A), 
with DiO stained A549 cells (B) or DiO stained A549 cells infected with 100 MOI of Ad- Cab (C). Trogocytosis of six different cells 
lines infected at 100 MOI (D) for 48 hours with indicated virus and PMNs added. Neutrophils alone or neutrophils coincubated 
with DiO stained target cells were used as controls. PMNs were added at an E:T ratio of 40:1. DiO +PMNs were then calculated 
using flow cytometry. ADCC, antibody- dependent cell phagocytosis; PMN, polymorphonuclear.
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expressing 4T1 and MDA- MB-436 cells had already been 
eliminated when each component of the immune system 
was added individually. To examine this, PD- L1 expres-
sion on 4T1 and MDA- MB-436 cells was further increased 
by treating cells overnight with IFN- gamma before setting 
the ADCC assays.28 As anticipated, a higher tumor killing 
could be observed with all immune components added 
individually or in combination with IFN- gamma treated 
Figure 4 Activation of multiple branches works in synergy leading to enhanced cytotoxicity. (A) Histograms demonstrating 
the percentage PD- L1 expression on all cell lines used in the assays. Cell lysis of tumor cell lines in the presence of (B) 
PBMCs +PMNs and (C) PBMCs+PMNs+serum . PBMCs and PMNs were added at an E:T ratio of 40:1 and 100:1, respectively, 
while serum was added at 15.5%. Cells were infected with viruses at 100 MOI and incubated for 48 hours or 10 µg/mL of 
antibody were added 30 min prior to adding immune components. Lysis was then detected using an LDH release assay. Levels 
of significance were set at *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Error bars represent SD. PBMC; peripheral blood 
mononuclear cell; PMN, polymorphonuclear.
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4T1 and MDA- MB-436 cells. Like the other cell lines, with 
the IFN- gamma treated cells, Ad- Cab was able to activate 
PMNs and induce higher killing with both combinations 
(PBMC+PMN and PBMCs+PMNs+serum) compared with 
IgG1 PD- L1.
To further verify such data, we performed both live- 
cell microscopy and impedance- based real- time quantita-
tive analysis (XCELLigence) to track target cells treated 
with purified Fc- fusion peptide (Ad- Cab) or therapeutic 
antibodies (Atezolizumab and IgG1- PDL1) following the 
addition of PBMCs and PMNs. With live- cell microscopy, 
A549 cells were monitored for 12 hours, and death was 
determined using a Caspase-3/7 Green Reagent and 
phase confluency. At E:T ratios of 10:1 and 4:1, PBMCs 
and PMNs, respectively, live- cell imaging supported the 
LDH release data since apoptosis was observed when 
IgG1- PD- L1 or Ad- Cab was added (online supplemental 
figure S4A and online supplemental movie S3-5). More-
over, cell death was further enhanced with Ad- Cab 
compared with IgG1- PDL1 (online supplemental file 4). 
Using XCELLigence, we analyzed cell- killing in real time 
(online supplemental figure S5A–E) and calculated the 
rate of cell death for each therapeutic antibody (IgG1- or 
IgA- PD- L1) and purified Fc- fusion peptide. The purified 
Fc- fusion peptide (Ad- Cab) had the highest killing rate 
in all cell lines, ranging from 0.0361 to 0.0482, compared 
with IgG- PD- L1 (0.0221–0.0289) and IgA- PD- L1 (–0.0186 
to 0.0282) (online supplemental figure S5F). Hence, 
we demonstrated that the Fc- fusion peptide augment 
immune- mediated apoptosis compared with IgG1- PD- L1, 
IgA- PD- L1 and the clinically used Atezolizumab in real 
time analysis.
Other than cancer cells, immune cells also express 
PD- L1, especially myeloid cells. To test whether Ad- Cab 
could affect such cells, purified IgGA Fc fusion peptide 
was added in unprocessed whole blood of three healthy 
donors and incubated for 24 hours. In these conditions, we 
would be able to test whether the Fc- fusion peptide could 
induce lysis of any immune population in the presence of 
all physiological effector populations (NK cells, neutro-
phils or complement system). After 24 hours, samples 
were processed and stained, and counting beads were 
added to determine the absolute numbers of DCs, NK 
cells, neutrophils, T cells and monocytes (online supple-
mental figure S6A). Ad- Cab was shown not to induce 
cytotoxicity to any cell population since the percentages 
and absolute numbers were similar to untreated or Tras-
tuzumab (anti Her-2 IgG) treated samples in all three 
donors (online supplemental figure S6B).
In vivo efficacy of Ad-Cab with CT26 and A549 tumor model
Based on the in vitro data, we decided to test the efficacy of 
Ad- Cab in vivo using a syngeneic mice model. Mice do not 
express Fc-α receptors, hence not allowing to test the full 
efficacy of the Fc- fusion peptide. Nevertheless, due to the 
homology of human and murine Fc-γ receptors, the IgG 
portion of the Fc- fusion can be tested. The colon carci-
noma CT26 model was used since it has been reported 
not to respond effectively to PD- L1 checkpoint therapy 
and the advantages of Ad- Cab could be more apparent in 
this model.29 30 After 7 days postengraftment, mice were 
treated either with PBS, Ad-5/3Δ24, Ad- Cab or mPD- L1 
for a total of 7 times (figure 5A). As expected, Ad- Cab 
was shown to be the most effective group in controlling 
tumor growth (figure 5B). Also, mice treated with mPD- L1 
were shown to control tumor growth better than mock; 
however, this was not statistically significant. We also 
calculated a therapeutic threshold based on the average 
of the tumor growth of mice treated with Ad-5/3-Δ24 
and mPD- L1 since Ad- Cab represents a combination of 
both treatments. Based on this, all the mice treated with 
Ad- Cab were responders showing a superior efficacy 
compared with mPD- L1(online supplemental figure 
S7A). The efficacy of Ad- Cab could also be translated to 
an enhanced overall survival compared with all the other 
treatment groups (figure 5C). Due to toxicity concerns, 
we analyzed the weight of the mice and distribution of the 
antibody for each group. No significant weight changes 
could be seen among the groups (online supplemental 
figure S7B). Moreover, because the Fc fusion peptide was 
tagged with an 8xHis, we monitored the distribution in 
the blood and tumor. After the mice had received four 
treatments, two mice from each group were sacrificed and 
their blood and tumors were collected to detect the Fc- fu-
sion peptide. In blood (figure 5D), undetectable levels 
of his- tagged Fc- fusion peptide could be observed in all 
groups. However, in the tumor (figure 5E), only in the 
Ad- Cab group an average of 2 µg/mL of his- tagged Fc- Fu-
sion peptide could be found. After observing that from 
the Ad- Cab and mPD- L1 treated groups, some mice were 
tumor free, we decided to rechallenge the mice with CT26 
to assess if a memory response had been formed. Mice 
previously treated with mPD- L1 had a successful tumor 
implantation, yet the growth was reduced compared with 
naïve mice injected with CT26 (figure 5F). Interestingly, 
mice treated with Ad- Cab rejected the tumor since no 
tumor was visible up to 30 days. This indicated that the 
surviving mice from the Ad- Cab group had formed a 
memory response able to control a rechallenge of CT26.
We went on to further characterize Ad- Cab in a 
human tumor xenograft model with immune deficient 
NS (NOD/SCID) mice reconstituted with a human 
immune system. NS mice were first implanted with A549 
cells and also injected with freshly isolated PBMCs from 
the same donor (figure 5G). After tumors had been 
engrafted, peripheral blood was taken from the mice to 
check for human immune cells engraftment. It was seen 
that human CD45 and CD3 cells were circulating in the 
peripheral blood of the mice, suggesting that the engraft-
ment with human PBMCs was successful (online supple-
mental figure S8). Mice were treated with either PBS, 
Ad-5/3 Δ24 or Ad- Cab for two treatments. Mice treated 
with unarmed oncolytic adenovirus had a better tumor 
control compared with mock (figure 5H). Yet, mice 
treated with Ad- Cab had a statistically significant tumor 
control compared with all other groups. Similar with the 
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CT26 mice, his- tagged Fc- fusion peptide was not found in 
the blood (figure 5I) in any group but in the tumors of 
Ad- Cab treated mice around 2–4 µg of his- tagged protein 
was observed (figure 5J). By analyzing the tumor micro-
environment, we observed that mice treated with Ad- Cab 
had an increase in both NK and CD8 + T cells which were 
positive for CD107a (figure 5K). This indicated that these 
cells had been activated and degranulated perforins and 
granzymes. These data demonstrate the enhanced in vivo 
efficacy and good safety profile of Ad- Cab.
Ad-Cab controls 4T1 tumor growth despite CD8+ T cell 
depletion
After observing that Ad- Cab was successful in controlling 
CT26 and A549 tumors in vivo, we decided to test it 
against 4T1 which is a highly immunosuppressive, fast 
growing and metastatic tumor. Mice bearing 4T1 tumors 
were treated with the same treatments and dosing as with 
the CT26 mice (figure 6A). Mice treated with Ad- Cab 
showed the best tumor control over all other groups. 
mPD- L1 treated mice also showed a degree of tumor 
Figure 5 Tumor efficacy and biodistribution of Ad- Cab in syngeneic mouse model CT26 colon carcinoma and xenograft model 
A549. (A) Schematic diagram of treatment schedule. Mice were treated either with PBS (mock), Ad-5/3Δ24, Ad- Cab or mPD- L1 
after 7 days postengraftment of 5×106 cells in the right flank of the mice. Treatments were given on days 7, 9, 11, 13,17, 19 
and 21. Ad-5/3Δ24 and Ad- Cab were given intratumorally at a dose of 1×109 viral particles while 100 µg of mPD- L1 was given 
intraperitoneally. (B) Summary data for average tumor growth for all treatment groups for CT26 tumor model. (C) Kaplan- Meier 
survival curve for the treatment groups. Concentration of His- tagged PD- L1 Fc- fusion peptide in blood (D) and tumor (E) from 
two mice per each group. Dotted line represents the detection limit of the kit. (F) CT26 tumor free mice were rechallenged with 
500,000 CT26 cells and tumor growth was recorded. (G) Schematic diagram of treatment schedule A549 model. Mice were 
implanted with tumors and human PBMCs and then treated with PBS (mock), Ad-5/3Δ24 or Ad- Cab. Treatments were given 
on days 9 and 12 at a dose of 1×109 viral particles intratumorally.(H) Summary data for average tumor growth for all treatments 
with A549 bearing mice. Concentration of His- tagged PD- L1 Fc- fusion peptide in blood (I) and tumor (J) from two mice per 
each group. (K) CD8 + T cell and NK cell degranulation (CD107a) and exhaustion (PD-1) markers were examined in the tumor 
microenvironment. A two- way ANOVA was conducted along with a Dunnett’s test to test significance. The number of mice per 
each group was 9–10. Levels of significance were set at *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Error bars represent 
SD. ANOVA, analysis of variance; NK, natural killer; PBMC; peripheral blood mononuclear cell.
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Figure 6 Ad- Cab induces 4T1 tumor control in vivo in presence and absence of CD8 + T cells. (A) Schematic diagram of 
treatment schedule for 4T1 bearing mice. Mice were treated either with PBS (mock), Ad-5/3Δ24, Ad- Cab or mPD- L1 after 
7 days postengraftment of 3×105 cells in the right flank of the mice. Treatments were given on days 7, 9, 11, 13,17, 19 and 
21. Ad-5/3Δ24 and Ad- Cab were given intratumorally at a dose of 1×109 viral particles while 100 µg of mPD- L1 was given 
intraperitoneally. (B) Summary data for average tumor growth for all treatment groups for 4T1 tumor model. (C) Granulocytic 
(CD11b+Ly6 Ghi Ly6C-) and monocytic (CD11b+Ly6 Chi Ly6G-) MDSC infiltration in 4T1 tumor microenvironment. Cell 
percentages of granulocytic (D), monocytic (E) MDSC and TAM (F). NK cell activation (G,H) and CD8 (I) cell activation was 
determined using the CD107a degranulation marker. CD8 + T cell exhaustion was also measured using PD1 (J). (K) Schematic 
diagram of treatment (black arrows) and CD8 depletion (red arrows) schedule for 4T1 bearing mice. Treatment scheduled was 
the same as previously but 1 day before treatment 500 µg of CD8 depleting antibody was given and then every 2 days 100 µg 
was given. (L) CD8 and CD4 cell staining on CD3 gated peripheral blood from mice treated with or without depleting CD8 
antibody. (M) Summary data for average tumor growth for all treatment groups for CD8 depleted 4T1 tumor model. (N) Kaplan- 
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control, yet it was not significant compared with mock 
(figure 6B). After sacrificing the mice, the tumor micro-
environment was analyzed for different immune popu-
lations and activation/exhaustion markers. As expected, 
4T1 tumors were highly infiltrated with both immuno-
suppressive monocytic (CD11b+Ly6 Chi Ly6G-) and 
granulocytic (CD11b+Ly6 Ghi Ly6C-) myeloid- derived 
suppressor cells (MDSC) which is in line with previous 
reports (figure 6C). Surprisingly, there was a significant 
reduction in both granulocytic MDSC (figure 6D) and 
monocytic MDSC (figure 6E) cell populations in the 
Ad- Cab treated group compared with other groups. 
Moreover, this reduction in the Ad- Cab treated group 
was accompanied with a higher infiltration of NK cells 
compared with the rest of the groups (online supple-
mental figure S9). No increase of other cell types such as 
dendritic cells, CD8 T- cells, CD4 T- cells (online supple-
mental figure S9) or tumor- associated macrophages 
(TAMs) (figure 6F) was observed since the percentage 
of cells was similar among all groups. We then analyzed 
the activation of both CD8 + T cells and NK cells using 
the cytotoxic degranulation marker CD107a (figure 6G). 
A clear increase of NK activation and degranulation 
could be observed in Ad- Cab treated groups (figure 6H). 
This was also seen with the CD8 T cells with the Ad- Cab 
treated group but as well with the mPD- L1 treated group 
(figure 6I). Other than being activated, CD8 T- cells 
displayed an exhausted phenotype in both Ad- Cab and 
mPD- L1 group with the latter being higher in expressing 
exhaustion marker PD1 (figure 6J). This implies that 
both Ad- Cab and mPD- L1 were able to activate and 
degranulate CD8 + T cells against the tumor but Ad- Cab 
was also able to do so with NK cells as well.
Having observed that Ad- Cab was able to strongly acti-
vate NK cells, we wanted to further characterize their 
mechanism of action in vivo by repeating the same exper-
iment with 4T1 but depleting CD8 T cells. Mice were 
first given a high dose of CD8 depleting antibody before 
starting treatment and kept receiving the depleting 
antibody during the treatment schedule to make sure 
CD8 T cells were absent during the treatment schedule 
(figure 6K). After the first treatment, peripheral blood 
was taken from mice to check that no circulating CD8 T 
cells were present. Depletion was shown to be successful 
as no circulating CD8 T cells could be observed in 
mice receiving CD8 depleting antibody compared with 
those that were not (figure 6L). As expected, mPD- L1 
treated mice showed a similar tumor growth compared 
with mock and Ad-5/3 Δ24 treated mice. Nevertheless, 
Ad- Cab treated mice had a significantly lower tumor 
growth compared with all other groups (figure 6M). 
This was also translated to higher overall survival in the 
Ad- Cab treated group (figure 6N). This indicates that, 
in contrast to checkpoint inhibitors, Ad- Cab does not 
solely require CD8 T cells to induce tumor killing in 
vivo.
Characterization of patient-derived RCC organoids as testing 
platforms for Ad-Cab
To further study the contribution of the IgA portion of 
Ad- Cab, we developed a novel testing platform using 
RCC PDOs. Freshly dissociated tumor tissue from four 
patients (RCC1-4) undergoing radical nephrectomies 
were obtained. Samples were grown either as 2D in 3D 
by embedding cells in Matrigel (figure 7A). In order to 
assess the heterogeneity of the PDOs and to compare 
them to the corresponding tumor tissue that they orig-
inated from, we stained PDO cells that were allowed to 
grow as 2D on plastic with three commonly used stains to 
differentiate RCC (CAIX, Vimentin and Cytokeratin) and 
with an F- actin stain (Phalloidin) (figure 7B). Both CAIX 
and vimentin are highly sensitive and specific for clear 
cell renal cell carcinoma (ccRCC).31 This is consistent 
with the staining since RCC2, RCC3 and RCC4 samples 
were shown to be positive for CAIX and vimentin and 
were characterized as ccRCC at the time of diagnosis. 
Surprisingly, RCC1 was both CAIX and vimentin posi-
tive despite being classified as a chromophobe RCC, a 
subtype that usually is not CAIX or vimentin positive. Yet, 
RCC1 had a focal expression of CAIX and lower expres-
sion of vimentin compared with the other samples, where 
staining was more diffused.
Subsequently, we tested whether oncolytic adenoviruses 
had the ability to pass through the Matrigel and infect the 
organoids. To this end, we infected PDOs with an oncolytic 
adenovirus expressing the red fluorescent protein (Ad5-Δ 
24- RFP) to visualize the infection and the replication of 
the virus (figure 7C, online supplemental figure S10A–
C). The virus was added on top of the supernatant of the 
PDO cultures and after 1 day PDOs were already infected 
and expressing RFP. Expression kept increasing until 
reaching a maximum on day 3. To confirm whether the 
virus could induce oncolysis, a viability cell stain, Calcein 
AM, was added and monitored (figure 7C). Oncolysis was 
observed to start at day 3 with minimal death occurring, 
and by day 4, most cells were shown to be dead. To finalize 
the testing platform, we tested whether isolated PBMCs 
could travel through the Matrigel and surround the 
organoids. Before their addition to the organoid cultures, 
PBMCs were labeled with Calcien green and then added 
on top of the media (figure 7D). Within hours, they could 
be seen to pass through the Matrigel and surround organ-
oids. Finally, PD- L1 expression was then tested by dissoci-
ating the PDOs into single cells and evaluating expression 
using flow cytometry (figure 7E). Varying levels of expres-
sion of CD3-/PD- L1 +positive cell were shown from the 
samples, from 20% to 66%. Hence, we demonstrate that 
the RCC PDOs can be used as testing platforms for the 
Ad- Cab virus, and since they express PD- L1, they can 
be infected by oncolytic adenoviruses and infiltrated by 
PBMCs.
After optimizing the RCC organoids as a functional 
testing platform for the Ad Cabs, we used them to 
perform the ADCC experiments with PBMCs and PMNs 
(figure 7F). RCC organoids were first infected with the 
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Figure 7 Characterization of Ad- Cab in RCC patient- derived organoids. (A) Representative imaging of renal cancer cell tissue 
grown in Matrigel as 3D (left) and 2D (right). Immunofluorescence staining of dissociated RCC PDOs using CAIX, Cytokeratin, 
Vimentin, CD3 and Phalloidin. Scale bar 500 or 200 µm. (C) RCC2 PDOs were infected with 5×105 vp of Ad5- RFP Δ24. Cell 
viability was visualized using Calcein green. Scale bars 200 µm. (D) Images of RCC2 PDOs infiltrated by Calcein green stained 
PBMCs. 105 PBMCs, stained with Calcein green, were added on top of Matrigel and after 4 hours images were taken using an 
EVOS FL cell imaging system. Scale bars 400 or 200 µm. (E) FACS analysis of PD- L1 expression of dissociated RCC PDOs. (F) 
ADCC assays with RCC1, RCC2, RCC3 and RCC4 PDOs. RCC PDOs were infected with viruses at 100 MOI and incubated for 
48 hours or 10 µg/mL of antibody were added 30 min prior to adding immune components. PBMCs and PMNs were added at 
an E:T ratio of 40:1 and 100:1, respectively. LDH release assays were performed 4 hours after addition of immune effector cells. 
ADCC, antibody- dependent cell cytotoxicity; PBMC, peripheral blood mononuclear cell; PDO, patient- derived organoid; PMN, 
polymorphonuclear; RCC, renal cell carcinoma.
copyright.
 on A















16 Hamdan F, et al. J Immunother Cancer 2021;9:e003000. doi:10.1136/jitc-2021-003000
Open access 
viruses or treated with the antibodies and incubated for 
3 days. As evident from the ADCC results, when PBMCs 
were added to the organoids, similar levels of cytotoxicity 
were observed with the Ad- Cab and the IgG1 PD- L1 anti-
body. Consistent with in vitro data, cytotoxicity could only 
be observed with the Ad- Cab and not with the IgG1 PD- L1 
antibody when PMNs were added as the effector cells 
(figure 7F). When both populations of effector cells were 
added simultaneously, there was an enhanced cell killing 
with Ad- Cab compared with when each population was 
added individually (figure 7F), with all samples except 
RCC1 (figure 7F). This could be explained by the fact that 
all PD- L1 expressing cells were killed when each effector 
population was added individually. The added benefit of 
activating an additional effector population with Ad- Cab 
was evident since the killing efficiency in RCC2, 3 and 
4 patient samples were greater when PBMCs and PMNs 
were added together. Thus, the PDOs further reinforced 
the efficacy of Ad- Cab and the significance of the syner-
gism of the immune system for tumor eradication.
DISCUSSION
ICIs have emerged as a major clinical milestone for the 
treatment of cancer. However, recent data have revealed 
that the in vivo activity of such antibodies solely depend 
on the Fab- mediated inhibition of inhibitory immune 
checkpoints and also the effector mechanisms medi-
ated by the Fc portion.32–34 In this study, we designed a 
novel PD- L1 ICI with a cross- hybrid Fc region mediating 
effector mechanisms of both an IgG and an IgA. To mini-
mize unwanted cytotoxicity, the novel ICI was cloned into 
a conditionally replicating adenovirus to limit release 
only to the tumor microenvironment. Ad- Cab secreted 
the cross- hybrid IgGA Fc- fusion peptide able to bind to 
PD- L1 and activate multiple immune pathways, not acti-
vated when IgG or IgA antibody is added alone, resulting 
in enhanced tumor killing in various in vitro, in vivo and 
ex vivo models.
As expected, the additive effector mechanisms of the 
Fc- fusion peptide increased tumor killing when compared 
with the FDA approved IgG, Atezolizumab, containing an 
N298A mutation abrogating Fc-γ binding. In line with 
other studies, the additive effector functions of the Fc- fu-
sion peptides against PD- L1 holds potential into greater 
clinical results.9 10 Based on in vitro and in vivo analysis, 
a crucial mechanism of action of several therapeutic anti-
bodies against cancer is to elicit tumor cell killing via ADCC 
and CDC.35 As for ICIs, including a functional Fc region 
may not always be beneficial and depends on the immune 
checkpoint receptor targeted. For example, equipping 
CTLA-48 and PD- L1 ICIs9 10 with a competent Fc region 
able to elicit ADCC has been shown to enhance efficacy 
yet with PD-1 antibodies, it reduced efficacy. Coinciding 
with previous results, we also show that incorporating 
effector mechanisms to PD- L1 ICIs increases efficacy due 
to enhanced tumor killing. Our results demonstrate that 
mice bearing CT26 and 4T1 tumors responded better 
to Ad- Cab compared with mPD- L1. This superiority is 
hypothesized to be due to the enhanced Fc- effector 
mechanisms since the Fc- fusion peptide is partly human 
IgG1 and such isotype induces greater ADCC compared 
with IgG2a (isotype of mPD- L1) in mice.12 This coin-
cides with our data showing an enhanced activation of 
NK cells when treated with Ad- Cab compared with mPD- 
L1. Moreover, when CD8 T cells were depleted, mPDL1 
was not able to control anymore the tumor growth yet 
Ad- Cab was able. This is mostly due to the engagement of 
other immune cells such as NK cells as an effector popu-
lation by Ad- Cab. Other than augmenting tumor cell 
killing, Ad- Cab was also shown to stimulate an antitumor 
memory response since CT26 recovered mice treated 
with Ad- Cab did not engraft a second challenge of CT26. 
The augmented tumor cell killing could have resulted in 
the excess release of tumor antigens being picked up by 
infiltrated dendritic cells. Therefore, other than having 
a local impact, the increased tumor cell killing by the 
engagement of multiple effector population could lead 
to a systemic effect.
Interestingly, Ad- Cab was able to affect the tumor micro-
environment by reducing highly immunosuppressive cell 
populations such as monocytic MDSCs and granulocytic 
MDSCs in 4T1 bearing mice. Such cell populations have 
been attributed to enhanced tumor growth, suppressing 
pre- existing antitumor responses and impeding the effi-
cacy of many cancer immunotherapies. It is believed 
that Ad- Cab was able to reduce such immunosuppressive 
immune populations due to their abnormally high expres-
sion of PD- L1. Even though other myeloid cells such as 
dendritic cells, macrophages, monocytes or neutrophils 
express PD- L1, they were unharmed by Ad- Cab both in 
vitro and in vivo. These results fall in line with previous 
studies and have contributed to the number of PD- L1 
molecules expressed on the cell membrane which is a 
key determinant for antibody effector functions. Hence, 
other than increasing tumor cell killing, Ad- Cab is also 
able to counteract suppressive immune populations 
highly expressing PD- L1.
Despite the fact that neutrophils express activating 
Fc-γIIA, able to trigger ADCC, the cells also express 
one log more of Fc-γIIIB.36 Unlike other Fc-γ receptors, 
the Fc-γIIIB receptor does not contain either activating 
(ITAM) or inhibitory (ITIM) motifs and its role has 
been questioned. Nevertheless, with therapeutic anti-
bodies against cancer, it has been attributed to act as a 
molecular “sink” by competitively binding to IgG with 
no resulting activation.12 13 37 Yet, the Fc- fusion peptide 
was able to capitalize on such a neglected cell population 
due to their high expression of Fc-α. Neutrophils are 
the most abundant leukocyte population in blood and 
tumorigenesis skews hematopoiesis towards neutrophil 
production by secreting granulocyte- colony stimulating 
factor (G- CSF) and granulocyte- macrophage- colony 
stimulating factor (GM- CSF) leading to tumor infiltra-
tion.38–40 Regardless of their high tumor infiltration, these 
cells have shown to be protumorigenic and their tumor 
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infiltration has been associated with a low clinical prog-
nosis.41 This associated low prognosis is due to the lack 
of effective neutrophil- activating stimulus and the immu-
nosuppressive tumor microenvironment polarizes the 
cells towards pro- tumorigenic.39 Many studies have shown 
that the tumor microenvironment can direct the fate of 
neutrophils towards either antitumorigenesis or protum-
origenesis.42–44 Hence, the ability of Fc- fusion peptide to 
activate neutrophils can polarize already tumor- infiltrated 
neutrophils from tumor- promoting to tumor- killing cells. 
Subsequently, the activation of neutrophils can lead 
to the release of multiple cytokines and chemokines to 
recruit other effector immune cells45 that the Fc- fusion 
peptide can further activate. Unfortunately, since mice do 
not express endogenous Fc- alpha receptors, the full effi-
cacy of Ad- Cab could not be studied in vivo. In the future, 
transgenic mice expressing Fc- alpha receptors should be 
used to fully assess the efficacy of Ad- Cab. Other than 
eliminating, it would be interesting to examine whether 
the activation of Fc- alpha receptors on granulocytic or 
monocytic MDSC could help polarize such cell to be 
antitumorigenic.
To extensively evaluate the efficacy of the Fc- fusion 
peptide, we used RCC PDOs. PDOs have revolutionized 
the study of cancer since analysis of patient- derived tissue 
can be done without invasive procedures. Additionally, 
PDO cultures have allowed to test individual responses 
of patients ex vivo with a high sensitivity and specificity 
in multitude types of tumors.46 47 This is because the 
PDOs can mimic tumor heterogeneity with respect to 
genetics and architecture often lacking with in vitro cell 
lines and animal models.48 To our knowledge, currently 
there are only two published studies that have evaluated 
the efficacy of oncolytic viruses using PDOs.49 50 This is 
the first study where the efficacy of the oncolytic virus 
was tested and an ADCC assay was performed. PDO data 
further demonstrated the added efficacy of the Fc- fu-
sion peptide by eliciting ADCC with PBMCS and PMNs. 
This dual activation of both populations was also shown 
to augment tumor killing compared with when each 
population was added individually, or one population 
was only activated by the IgG1 PD- L1. Hence, these data 
have broadly evaluated the preclinical efficacy of the 
Fc- fusion peptide.
This synergistic effect by simultaneously engaging Fc-α 
and Fc-γ was also shown by Brandsma and colleagues,17 
when IgA and IgG antibodies against two different tumor- 
associated antigens (TAAs) were added and a higher 
tumor killing was observed compared with when each 
antibody was used individually. Interestingly, this effect 
was only seen when the antibodies were directed towards 
two different TAAs and diminished when they were 
directed towards the same TAA. From data presented in 
this study, it can be deduced that this diminished effect 
could have been due to the competitive binding between 
the IgG and IgA antibodies towards the same epitope, 
since this synergistic effect was shown in the Fc- fusion 
peptide that incorporated both an IgG and IgA.
In conclusion, here we demonstrate a novel ICI, with 
enhanced tumor killing efficacy, expressed from an onco-
lytic adenovirus to limit toxicities. We have shown that 
the Fc- fusion peptide is able to activate PBMCs, usually 
activated by IgG1 antibodies, and engage a neglected but 
important population, PMNs. This coengagement of both 
populations was shown to work in synergy augmenting 
tumor killing in various PD- L1 expressing cell lines and 
RCC PDOs. Such preclinical results prompt the further 
investigation of Ad- Cab towards the path of clinical 
development.
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